HIGHLIGHTS
- who: Qiongli Ding from the Critical Medicine Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, China have published the Article: Clinical Utility of the Sivelestat for the Treatment of ALI/ARDS: Moving on in the Controversy?, in the Journal: (JOURNAL)
- how: The results showed that sivelestat therapy might play an important role on the PaO2/FiO2 level while it had no significant effect on 28-30 days mortality ventilation days and ICU stays. The results showed that sivelestat improved lung injury score PaO2/FIO2 ratio DIC score and ICU . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.